Quick Answer
Telix Pharmaceuticals Ltd reported R&D Expense of $171.25 million for fiscal year 2025.
Telix Pharmaceuticals Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $171.25M | +33.9% |
| 2024 | $127.93M | +50.0% |
| 2023 | $85.31M | +5.7% |
| 2022 | $80.69M | — |
- Telix Pharmaceuticals Ltd showed an increase of +33.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Telix Pharmaceuticals Ltd’s r&d expense has grown by 112.2% (from $80.69 million to $171.25 million).
- The most recent figure is from Telix Pharmaceuticals Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: